National Institute on Aging
31 Center Drive, MSC 2292
Building 31, Room 5C27
Bethesda
Maryland
20892
United States
Tel: 301-496-1752
Website: http://www.nia.nih.gov/
67 articles about National Institute on Aging
-
Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the NIA-sponsored CLARiTI Trial
11/6/2023
Meilleur Technologies, Inc. today announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).
-
CHA Hollywood Presbyterian to Participate in $40 Million Study of Alzheimer's Disease in Persons of Korean, Vietnamese, and Chinese Ancestry
7/11/2023
CHA Hollywood Presbyterian Medical Center is proud to announce its participation in a prestigious $40.5 million, multisite study funded by a grant from the National Institute on Aging, part of the National Institutes of Health, for the development of the Asian Cohort for Alzheimer’s Disease.
-
Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease
10/4/2022
Praetego Inc is pleased to announce a $2.5M STTR award from the National Institute of Aging.
-
Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010
10/4/2022
Oligomerix, Inc. announced an award of $2.49 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
-
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
9/27/2022
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease.
-
NIH researchers found that symptomatic herpes viruses were associated with neurological symptoms, but there was no evidence that herpes viruses are linked to Alzheimer’s disease.
-
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
8/9/2022
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $3.35 million from the National Institute on Aging of the National Institutes of Health to support clinical development of its lead program OLX-07010, an oral tau self-association small molecule inhibitor.
-
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
-
An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.
-
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer's patients.
-
LifeBio Secures Second National Institute on Aging Grant; Research Will Use Artificial Intelligence as a Possible Diagnostic Tool for Alzheimer's
10/12/2021
LifeBio announced its second National Institute on Aging (NIA) Small Business Innovation Research (SBIR) grant of $448,462 to focus on the Alzheimer's disease population.
-
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer's. Know more about it here.
-
Feinstein Institutes Receives $1.7M Grant to Study Behavior Change Science, Promote Exercise in Older Adults
9/9/2020
Only half of the adults in the United States get the exercise they need to help reduce and prevent chronic diseases.
-
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
-
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Researchers with the National Institute on Aging published research of a gene variant, APO3 Christchurch (APOE3ch), that appears to confer resistance to Alzheimer’s disease.
-
What is the best way to prevent or even reverse Alzheimer’s disease? That’s the question at the top of many researchers’ minds, especially given all of the recent large Phase 3 failures involving beta-amyloid targeting drugs, the most pursued target to date. This is troubling but not entirely sho...
-
Synthego Launches High-Throughput Induced Pluripotent Stem Cell Genome Engineering
10/22/2019
National Institutes of Health awards contract for CRISPR-based disease modeling in iPS cell lines associated with Alzheimer's, Stem cell pioneer Bill Skarnes joins advisory board
-
$53.4M Grant to Brown, Hebrew SeniorLife to Enable Massive Expansion of Alzheimer’s Research
9/10/2019
Federal grant from the National Institute on Aging will fund a collaborative research incubator to support trials across the nation aimed at improving care for people with dementia